科研製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2023/01/23 | 3,810 | 3,840 | 3,800 | 3,825 | +50 | +1.3% | 62,100 |
| 2023/01/20 | 3,780 | 3,790 | 3,760 | 3,775 | +15 | +0.4% | 35,000 |
| 2023/01/19 | 3,730 | 3,770 | 3,730 | 3,760 | +20 | +0.5% | 51,000 |
| 2023/01/18 | 3,735 | 3,770 | 3,725 | 3,740 | ±0 | ±0% | 60,400 |
| 2023/01/17 | 3,745 | 3,760 | 3,720 | 3,740 | +15 | +0.4% | 48,900 |
| 2023/01/16 | 3,690 | 3,755 | 3,690 | 3,725 | +20 | +0.5% | 46,700 |
| 2023/01/13 | 3,670 | 3,715 | 3,670 | 3,705 | +30 | +0.8% | 71,500 |
| 2023/01/12 | 3,685 | 3,685 | 3,655 | 3,675 | +15 | +0.4% | 38,100 |
| 2023/01/11 | 3,665 | 3,700 | 3,660 | 3,660 | -5 | -0.1% | 45,500 |
| 2023/01/10 | 3,710 | 3,725 | 3,665 | 3,665 | -10 | -0.3% | 69,500 |
| 2023/01/06 | 3,730 | 3,730 | 3,660 | 3,675 | -20 | -0.5% | 64,900 |
| 2023/01/05 | 3,750 | 3,760 | 3,695 | 3,695 | -85 | -2.2% | 82,400 |
| 2023/01/04 | 3,850 | 3,855 | 3,775 | 3,780 | -110 | -2.8% | 55,700 |
| 2022/12/30 | 3,925 | 3,930 | 3,890 | 3,890 | -25 | -0.6% | 32,200 |
| 2022/12/29 | 3,890 | 3,915 | 3,855 | 3,915 | +10 | +0.3% | 38,400 |
| 2022/12/28 | 3,895 | 3,920 | 3,880 | 3,905 | +15 | +0.4% | 43,500 |
| 2022/12/27 | 3,875 | 3,920 | 3,875 | 3,890 | +15 | +0.4% | 31,700 |
| 2022/12/26 | 3,890 | 3,890 | 3,865 | 3,875 | -15 | -0.4% | 24,000 |
| 2022/12/23 | 3,890 | 3,895 | 3,865 | 3,890 | ±0 | ±0% | 34,400 |
| 2022/12/22 | 3,860 | 3,895 | 3,820 | 3,890 | +35 | +0.9% | 44,600 |
| 2022/12/21 | 3,880 | 3,900 | 3,840 | 3,855 | -30 | -0.8% | 62,700 |
| 2022/12/20 | 3,890 | 3,915 | 3,840 | 3,885 | -25 | -0.6% | 91,700 |
| 2022/12/19 | 3,885 | 3,920 | 3,860 | 3,910 | +20 | +0.5% | 47,900 |
| 2022/12/16 | 3,900 | 3,925 | 3,880 | 3,890 | -25 | -0.6% | 78,200 |
| 2022/12/15 | 3,910 | 3,935 | 3,905 | 3,915 | ±0 | ±0% | 40,800 |
| 2022/12/14 | 3,930 | 3,945 | 3,900 | 3,915 | -10 | -0.3% | 39,700 |
| 2022/12/13 | 3,895 | 3,925 | 3,890 | 3,925 | +70 | +1.8% | 69,800 |
| 2022/12/12 | 3,870 | 3,880 | 3,845 | 3,855 | -40 | -1% | 46,500 |
| 2022/12/09 | 3,875 | 3,910 | 3,865 | 3,895 | +25 | +0.6% | 59,300 |
| 2022/12/08 | 3,860 | 3,885 | 3,835 | 3,870 | +10 | +0.3% | 56,100 |
| 2022/12/07 | 3,825 | 3,865 | 3,805 | 3,860 | +35 | +0.9% | 52,600 |
| 2022/12/06 | 3,815 | 3,835 | 3,815 | 3,825 | ±0 | ±0% | 50,500 |
| 2022/12/05 | 3,860 | 3,860 | 3,790 | 3,825 | -15 | -0.4% | 48,300 |
| 2022/12/02 | 3,885 | 3,885 | 3,815 | 3,840 | -80 | -2% | 68,600 |
| 2022/12/01 | 3,950 | 3,955 | 3,895 | 3,920 | -20 | -0.5% | 53,700 |
| 2022/11/30 | 3,935 | 3,960 | 3,920 | 3,940 | ±0 | ±0% | 85,500 |
| 2022/11/29 | 3,975 | 3,975 | 3,935 | 3,940 | -50 | -1.3% | 53,000 |
| 2022/11/28 | 4,000 | 4,000 | 3,960 | 3,990 | +15 | +0.4% | 55,400 |
| 2022/11/25 | 3,965 | 3,985 | 3,950 | 3,975 | +5 | +0.1% | 49,600 |
| 2022/11/24 | 3,990 | 4,005 | 3,970 | 3,970 | -30 | -0.8% | 74,000 |
| 2022/11/22 | 3,960 | 4,025 | 3,960 | 4,000 | +55 | +1.4% | 92,200 |
| 2022/11/21 | 3,930 | 3,955 | 3,925 | 3,945 | +40 | +1% | 60,200 |
| 2022/11/18 | 3,890 | 3,905 | 3,880 | 3,905 | +35 | +0.9% | 53,800 |
| 2022/11/17 | 3,825 | 3,875 | 3,825 | 3,870 | +60 | +1.6% | 56,500 |
| 2022/11/16 | 3,780 | 3,835 | 3,770 | 3,810 | +25 | +0.7% | 60,100 |
| 2022/11/15 | 3,770 | 3,810 | 3,770 | 3,785 | +15 | +0.4% | 55,900 |
| 2022/11/14 | 3,780 | 3,800 | 3,760 | 3,770 | -40 | -1% | 64,600 |
| 2022/11/11 | 3,820 | 3,830 | 3,785 | 3,810 | +50 | +1.3% | 87,700 |
| 2022/11/10 | 3,770 | 3,790 | 3,725 | 3,760 | -5 | -0.1% | 91,900 |
| 2022/11/09 | 3,745 | 3,765 | 3,720 | 3,765 | +45 | +1.2% | 72,100 |
601～
650
件表示中 / 3734件
類似銘柄と比較する
現在ご覧いただいている「科研薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 科研薬 | 379,000円 | -6.4% | -71.8% | 5.01% | 42.33倍 | 0.94倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の２本柱。後発品も展開 |
| キッセイ薬 | 399,000円 | +3.6% | +6.1% | 3.01% | 13.44倍 | 0.79倍 |
|
医薬品中堅。泌尿器、腎・透析、未充足医療が重点領域。主軸特許切れ、新しい柱育成。海外は導出 |
| 鳥居薬 | 632,000円 | +7.1% | -35.0% | 0.00% | 52.26倍 | 1.46倍 |
|
ＪＴ傘下。皮膚疾患や腎・透析、花粉症薬などアレルゲン領域に強み。塩野義製薬がＴＯＢ実施 |
| ジーエヌアイ | 311,500円 | +21.7% | +999.9% | 0.00% | 13.05倍 | 4.32倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
| サンバイオ | 217,100円 | - | - | 0.00% | - | 100.55倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
市場注目の銘柄
チャート関連のコラム
